The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Keynote-676: Phase 3 study of bacillus calmette-guerin (BCG) with or without pembrolizumab (pembro) for high-risk (HR) non–muscle invasive bladder cancer (NMIBC) that is persistent or recurrent following BCG induction.
 
Ashish M. Kamat
Honoraria - Pacific Edge
Consulting or Advisory Role - Abbott Molecular; Heat Biologics; Merck; Photocure; Sanofi; Spectrum Pharmaceuticals; Telesta Therapeutics; Theralase
Research Funding - FKD Therapies; Heat Biologics; Merck; Photocure
 
Neal D. Shore
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Dendreon; Ferring; Genentech/Roche; Janssen Scientific Affairs; Medivation/Astellas; Myovant Sciences; Pfizer; Tolmar
Speakers' Bureau - Bayer; Dendreon; Janssen
 
Noah M. Hahn
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Genentech/Roche; Health Advances; Inovio Pharmaceuticals; Merck; Oncogenex; Pieris Pharmaceuticals
Research Funding - Acerta Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Heat Biologics (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Oncogenex (Inst); Principa Biopharma (Inst)
 
Shaheen Alanee
Consulting or Advisory Role - AstraZeneca; Merck
Research Funding - Merck
Travel, Accommodations, Expenses - AstraZeneca
 
Hiroyuki Nishiyama
Speakers' Bureau - Chugai Pharma; Merck Sharp & Dohme
Research Funding - Astellas Pharma; Ono Pharmaceutical; Takeda
 
Shahrokh Shariat
Stock and Other Ownership Interests - UroGen pharma
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Cepheid; Ferring; Ipsen; Janssen; Lilly; Merck Sharp & Dohme; Olympus; Pfizer; Pierre Fabre; Ribon Therapeutics; Roche; Sanochemia; Sanofi; UroGen pharma
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Cepheid; Ferring; Ipsen; Lilly; Merck Sharp & Dohme; Olympus; Pfizer; Pierre Fabre; Ribon Therapeutics; Roche; Sanochemia; Sanofi; UroGen pharma
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Cepheid; Ferring; Ipsen; Janssen; Lilly; Merck Sharp & Dohme; Olympus; Pfizer; Pierre Fabre; Ribon Therapeutics; Roche; Sanochemia; Sanofi; UroGen pharma
Research Funding - AstraZeneca; Bayer; Bristol-Myers Squibb; Cepheid; Merck Sharp & Dohme; Roche
 
Kijoeng Nam
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Ekta Kapadia
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Tara L. Frenkl
Employment - Amicus Therapeutics (I); Merck
Leadership - Amicus Therapeutics (I)
Stock and Other Ownership Interests - Amicus Therapeutics (I); AstraZeneca; AstraZeneca (I); GlaxoSmithKline; GlaxoSmithKline (I); Merck
Travel, Accommodations, Expenses - Amicus Therapeutics (I); Merck
 
Gary D. Steinberg
Honoraria - Baxter; CG Oncology; Fidia Farmaceutici S. p. A.; Heat Biologics; MDxHealth; Merck; Photocure; Roche/Genentech; Taris Biomedical; Telesta Therapeutics
Consulting or Advisory Role - Boston Scientific; CG Oncology; Fidia Farmaceutici S. p. A.; Heat Biologics; MDxHealth; Merck; Natera; photocure; Roche/Genentech; Taris BioMedical